Introduction
============

Breast cancer is the most frequent cause of death in women in less-developed regions, which is different from more developed countries where it is the second cause of death (cancer related), after lung tumors.[@b1-bcbcr-10-2016-005] Median survival in patients with metastatic breast cancer (MBC) varies from 18 to 24 months,[@b2-bcbcr-10-2016-005]--[@b6-bcbcr-10-2016-005] even with the availability of several options of chemotherapy and biological therapy.[@b7-bcbcr-10-2016-005] At present, immunotherapy is probably the most promising option for expanding life expectations with the highest quality in these patients.

Gangliosides containing glycolylated sialic acid are not expressed in normal cells, but the presence of NGcGM3 has been reported in different human tumors, particularly in human breast tumors and metastasis,[@b8-bcbcr-10-2016-005],[@b9-bcbcr-10-2016-005] privileging this target for active-specific immunotherapy approaches due to its tumor-specific character.[@b8-bcbcr-10-2016-005],[@b10-bcbcr-10-2016-005]

Currently, an NGcGM3-based cancer vaccine, developed by the Center of Molecular Immunology by solubilization of the hydrophobic outer membrane proteins of *Neisseria meningitidis* with the ganglioside to form nanoparticles (very small-sized proteoliposomes (VSSP)),[@b11-bcbcr-10-2016-005] has been studied in two large Phase III trials with Stage III or MBC patients. For these clinical trials, an emulsive formulation of the NGcGM3/VSSP vaccine (containing Montanide ISA 51) is used, based on the previous evidences of safety and efficacy.[@b12-bcbcr-10-2016-005],[@b13-bcbcr-10-2016-005] In the meantime, an alternative nonemulsive formulation of the vaccine with less toxicity and probably increased efficacy was obtained.[@b14-bcbcr-10-2016-005] Then, we needed to decide quickly which formulation will continue the development process, and for this purpose, we conducted an Expanded Access (EA) program study, assuming all the limitations of this type of trial. The objective of the study was to reasonably find if the nonemulsive (SC) NGcGM3/VSSP vaccine could be significantly superior in safety and impact the overall survival (OS) of MBC patients, in comparison with the alternative emulsive (IM) formulation.

Material and Methods
====================

NGcGM3/VSSP vaccine
-------------------

NGcGM3/VSSP vaccine consists in VSSP obtained by the incorporation of NGcGM3 into the outer membrane protein complex of *N. meningitidis*. NGcGM3/VSSP has been studied in patients with advanced breast cancer as an emulsive formulation when used with Montanide ISA 51, at a dose of 200 μg IM.[@b12-bcbcr-10-2016-005],[@b13-bcbcr-10-2016-005] Recently, this vaccine has also been tested as a nonemulsive formulation (without Montanide ISA 51) at a dose of 900 μg SC in a study that included MBC patients.[@b14-bcbcr-10-2016-005] This optimal biological dose for the nonemulsive formulation was selected according to the results of efficacy, safety, and immunogenicity obtained in the study.[@b14-bcbcr-10-2016-005]

Study design
------------

An EA program study was designed to compare the results of OS and safety in patients treated with two different formulations of the vaccine. A total of 104 patients with progressive disease after the oncospecific first-line treatment for MBC were recruited at six clinical sites of investigation; 51 patients were treated with the nonemulsive formulation and 53 patients received the emulsive variant.

Randomization list was generated with the system Random Assignment ASAL (*ASignación ALeatoria* in Spanish) for Windows, version 1.2, and patients were randomly assigned to treatment groups according to the inclusion and exclusion criteria in the protocol. The randomization was centralized and not stratified by control variables.

Treatment consisted in the administration of NGcGM3/VSSP (nonemulsive formulation) or NGcGM3/VSSP/Montanide ISA 51 (emulsive formulation), by subcutaneous (900 μg/dose) or intramuscular (200 μg/dose) route, respectively. For both formulations, patients received the first five doses every two weeks and subsequent doses every four weeks.

Inclusion criteria
------------------

1.  Patients with cytohistological confirmation of breast cancer

2.  Patients in progression after the oncospecific first-line treatment

3.  Patients older than 18 years

4.  Patients who consent to participate in the study by signing the informed consent model

5.  Patients with ECOG Scale of Performance Status of ≤3.

Exclusion criteria
------------------

1.  Patients receiving other investigational product

2.  Patients who have criteria to be included in any ongoing clinical trial for this indication

3.  Patients who are pregnant or breastfeeding.

Ethical considerations
----------------------

The study was approved by the Ministry of Public Health (Cuba) and complied with the principles of the Declaration of Helsinki and Good Clinical Practice. A written consent for participating was required from each patient before his/her inclusion.

Evaluation during the study
---------------------------

Fisher's exact test for 2 × 2 tables and the chi-square test for 3 × 2 tables were used to assess the baseline patients' characteristics.

OS was estimated for all patients and was defined as the time from randomization until death from any cause; the results were analyzed by the Kaplan--Meier method. Common Toxicity Criteria to Evaluate Adverse Events, version 4.0, was used to classify according to the intensity of adverse events (AEs). AEs were also classified according to the System Organ Class (SOC) affected.

Results
=======

Patient population
------------------

A total of 104 patients were recruited in the study ([Table 1](#t1-bcbcr-10-2016-005){ref-type="table"}; [Fig. 1](#f1-bcbcr-10-2016-005){ref-type="fig"}). There was no statistical difference between both groups at the baseline, with the exception of the amount of patients who received chemotherapy during the primary tumor treatment (*P* = 0.0202) and the expression of estrogen (*P* = 0.0491) and progesterone (*P* = 0.0302) receptors. We consider that the statistical difference evidenced in the hormonal receptors' status was due to the lack of information about this expression, with a greater percentage of patients in the nonemulsive formulation group in which the data were not available.

The mean age of patients was 60.9 and 56.3 years for the nonemulsive and emulsive formulations, respectively. In both arms of treatment, more than half of the patients were classified as nonstage IV disease (84.3%---nonemulsive formulation---and 67.9%---emulsive formulation). The most frequent histopathological type was ductal carcinoma, with 76.4% and 66.03% of cases for the nonemulsive and emulsive variants, respectively.

Most patients had received treatment when the primary tumor had been diagnosed and consisted of surgical resection, chemotherapy, and radiotherapy. For the metastatic disease, the most frequent treatment was chemotherapy. In both arms of the study, chemotherapy included the following: For the treatment of primary tumor: cyclophosphamide/methotrexate/5-fluorouracil (CMF), AC (doxorubicin/cyclophosphamide), docetaxel/carboplatin, and others.For the treatment of metastatic disease: CMF, docetaxel or paclitaxel/carboplatin, and others.

The expression of HER 2 and hormonal receptors was unavailable for most of the cases.

Efficacy results
----------------

In the intent-to-treat (ITT) analysis with the 104 patients, median OS was higher for patients treated with the nonemulsive formulation of the vaccine than for those treated IM, with 23.6 and 8.2 months, respectively (log rank *P* = 0.001; HR 95% CI: 0.450; [Table 2](#t2-bcbcr-10-2016-005){ref-type="table"}; [Fig. 2](#f2-bcbcr-10-2016-005){ref-type="fig"}).

An efficacy analysis was performed with the data from 93 patients according to the site of metastases, whether they were visceral or nonvisceral. In this analysis, median OS was superior for patients treated SC, in both the groups of patients with nonvisceral (log rank *P* = 0.118; HR 95% CI: 0.535) and visceral (log rank *P* = 0.005; HR 95% CI: 0.375) metastases ([Table 3](#t3-bcbcr-10-2016-005){ref-type="table"}; [Figs. 3](#f3-bcbcr-10-2016-005){ref-type="fig"} and [4](#f4-bcbcr-10-2016-005){ref-type="fig"}). In the subset of patients with nonvisceral metastases, median OS was 31.633 and 16.533 months for subcutaneous and intramuscular routes, respectively. Patients with visceral metastases had median OS of 21.033 and 6.267 months when treated by subcutaneous and intramuscular routes, respectively.

Another efficacy analysis was done with 85 patients by grouping them in patients diagnosed with Stage I or II, and patients with Stage III or IV ([Table 4](#t4-bcbcr-10-2016-005){ref-type="table"}; [Figs. 5](#f5-bcbcr-10-2016-005){ref-type="fig"} and [6](#f6-bcbcr-10-2016-005){ref-type="fig"}). Median OS was superior for patients treated with the nonemulsive formulation in both groups of patients. Interestingly, there was a significant statistical difference (log rank *P* = 0.002; HR 95% CI: 0.311) in the subset of patients with Stage I or II.

Safety results
--------------

A total of 524 AEs were reported: 416 for the nonemulsive formulation and 108 for the emulsive variant. The majority of AEs were classified into the *General Disorders and Administration Site Conditions* according to the SOC. Most frequent AEs ([Table 5](#t5-bcbcr-10-2016-005){ref-type="table"}) for both formulations were site reaction, asthenia, fever, headache, and chills. Other AEs included tachycardia (cardiac disorders), cough (reproductive system and breast disorders), vomiting (gastrointestinal disorders), and insomnia (psychiatric disorders). Most AEs were classified as grade I ([Table 6](#t6-bcbcr-10-2016-005){ref-type="table"}) and nonserious.

Discussion
==========

Since the announcement of the failure of Theratope in June 2003, introducing a cancer vaccine for MBC patients, treatment remains as a dream for immunoncologists. Although this STn-KLH-conjugated vaccine was well tolerated and able to induce a high rate of IgM and IgG seroconversion, the time to progression was 3.4 months in the treatment group and 3.0 months in the control group, and the median survival was 23.1 and 22.3 months, respectively.[@b15-bcbcr-10-2016-005]

To our knowledge at present, the most advanced active immunotherapy project in MBC is NGcGM3/VSSP. A first version of this vaccine comprised an additional emulsification with Montanide ISA 51, and its safety and immunogenicity was demonstrated in advanced breast cancer patients.[@b12-bcbcr-10-2016-005] The efficacy of this formulation was further assessed in a Phase II clinical trial in 80 MBC patients, achieving at least stable disease to the first-line therapy. While in the ITT analysis a modest trend toward a survival benefit for the vaccine group was observed, the most suggestive result came when patients were analyzed by the primary site of metastasis (visceral vs. nonvisceral). For patients with nonvisceral metastases, the median OS was 26.2 months for the vaccinated group and 12.2 months for the control group, but for patients with visceral metastases, no advantage in survival was associated with vaccination with the emulsive variant of NGcGM3/VSSP.[@b13-bcbcr-10-2016-005]

These results fueled the initiation of an ongoing controlled, double blinded, Phase III clinical study with this vaccine in the MBC patients. In the meantime, encouraging preclinical[@b16-bcbcr-10-2016-005] and preliminary clinical data[@b14-bcbcr-10-2016-005] were obtained with a nonemulsive formulation of the product, SC administered, introducing the need to decide which formulation should be chosen for continuing the product development.

For this purpose, a new study was designed under EA to Investigational Drugs' Principles, according to the Cuban regulatory agency (CECMED) regulation number 62 of 2012. A total of 104 MBC patients, who were nonresponders to the first-line oncospecific treatment, were divided to receive either the emulsive or the nonemulsive formulation of the NGcGM3/VSSP vaccine. Apart from the logical limitations imposed by the lack of information about hormonal receptors and HER 2 expression in the vast majority of the sample (due to the characteristics of EA), the striking difference in OS observed in these patients is more probably associated with the treatment. Median OS in the group of patients vaccinated with the nonemulsive variant of NGcGM3/VSSP almost triplicated the value in the alternative group of patients treated with the emulsive formulation. Moreover, the same notable advantage in survival in favor of patients SC vaccinated with the nonemulsive formulation was reproduced, irrespective if they have nonvisceral or visceral metastasis. Curiously, the insignificant impact on the survival of patients with visceral metastasis vaccinated with the emulsive variant of NGcGM3/VSSP, reported here, exactly reproduced the previous result obtained in the Phase II clinical trial.[@b13-bcbcr-10-2016-005] It is also to be noted that median OS was superior (log rank *P* = 0.002; HR 95% CI: 0.311) in patients treated with the nonemulsive formulation in the subset of patients with Stage I or II at diagnosis, irrespective of the site of metastasis after recurrence. It could be of interest to verify this finding in the future clinical trials.

In terms of safety, apart from the obvious more friendly condition of the nonemulsive formulation of the vaccine (with the removal of Montanide), 416 AEs were reported in patients injected with this variant, while 108 AEs were associated with the administration by the intramuscular route. A possible explanation of this difference could be that patients treated with the nonemulsive formulation notably survived longer and, for this reason, they received more number of injections. Besides, most AEs were classified as grade I and nonserious events. Most frequent AEs reported in patients treated with the two variants of the vaccine were reaction at the injection site, headache, asthenia, fever, and chills. This results reproduced previous ones,[@b12-bcbcr-10-2016-005]--[@b14-bcbcr-10-2016-005] confirming that the NGcGM3/VSSP vaccine is safe.

The results of this EA study sustained the decision to continue the NGcGM3/VSSP vaccine development with the nonemulsive formulation.

This work was supported by the Center of Molecular Immunology, Celestino Hernández Robau Hospital, José Ramón López Tabranes Hospital, Ramón González Coro Hospital, Vladimir Ilich Lenin Hospital, María Curie Hospital, and Conrado Benítez Hospital. We thank Dr. Yamilka Alberteri for her contribution to the study by including and treating patients. She is not listed as an author because she could not be contacted to give final approval for publication.

**ACADEMIC EDITOR:** Goberdhan P. Dimri, Editor in Chief

**PEER REVIEW:** Five peer reviewers contributed to the peer review report. Reviewers' reports totaled 1187 words, excluding any confidential comments to the academic editor.

**FUNDING:** Authors disclose no external funding sources.

**COMPETING INTERESTS:** Authors disclose no potential conflicts of interest.

Paper subject to independent expert blind peer review. All editorial decisions made by independent academic editor. Upon submission manuscript was subject to anti-plagiarism scanning. Prior to publication all authors have given signed confirmation of agreement to article publication and compliance with all applicable ethical and legal requirements, including the accuracy of author and contributor information, disclosure of competing interests and funding sources, compliance with ethical requirements relating to human and animal study participants, and compliance with any copyright requirements of third parties. This journal is a member of the Committee on Publication Ethics (COPE).

Provenance: The authors were invited to submit this paper.

**Author Contributions**

Conceived and designed the trial: AT, KP, and CEV. Included and treated patients: AT, ES, RR, LH, and DD. Delivered the product of investigation to clinical sites: YD and YGM. Monitored the trial: MA, MC, MD, LC, JLS, JJH, and ARV. Analyzed the data: CEV, LS, AMV, and MÁ. Wrote the manuscript: AMV, AT, and LEF. All authors reviewed and approved of the final manuscript.

![CONSORT diagram.](bcbcr-10-2016-005f1){#f1-bcbcr-10-2016-005}

![Kaplan--Meier curves for vaccinated patients.](bcbcr-10-2016-005f2){#f2-bcbcr-10-2016-005}

![Kaplan--Meier curves for vaccinated patients with nonvisceral metastases.](bcbcr-10-2016-005f3){#f3-bcbcr-10-2016-005}

![Kaplan--Meier curves for vaccinated patients with visceral metastases.](bcbcr-10-2016-005f4){#f4-bcbcr-10-2016-005}

![Kaplan--Meier curves for vaccinated patients with Stage I or II.](bcbcr-10-2016-005f5){#f5-bcbcr-10-2016-005}

![Kaplan--Meier curves for vaccinated patients with Stage III or IV.](bcbcr-10-2016-005f6){#f6-bcbcr-10-2016-005}

###### 

Patients' characteristics.

  PATIENTS CHARACTERISTICS                  FORMULATION     FISHER OR CHI-SQUARE TEST (*P*-VALUE)   
  ----------------------------------------- --------------- --------------------------------------- --------
  **Age (mean/range)**                      60.9 (41--81)   56.3 (36--84)                           0.065
  **Stage**                                                                                         
   Stage I                                  8 (15.6%)       7 (13.2%)                               0.1403
   Stage II                                 22 (43.1%)      13 (24.5%)                              
   Stage III                                13 (25.4%)      16 (30.1%)                              
   Stage IV                                 3 (5.8%)        3 (5.6%)                                
   Not available                            5 (9.8%)        14 (26.4%)                              
                                                                                                    
  **Histopathological type**                                                                        
   Ductal                                   39 (76.4%)      35 (66.03%)                             0.2822
   Lobular                                  0 (0%)          2 (3.7%)                                
   Medullary                                0 (0%)          1 (1.8%)                                
   Other                                    6 (11.7%)       4 (7.5%)                                
   Not available                            6 (11.7%)       11 (20.7%)                              
                                                                                                    
  **Treatment of primary tumor**                                                                    
   Surgery                                  44 (86.2%)      39 (73.5%)                              0.0545
   Chemotherapy                             42 (82.3%)      34 (64.1%)                              0.0202
   Radiotherapy                             35 (68.6%)      31 (58.4%)                              0.0917
                                                                                                    
  **Treatment of metastatic disease**                                                               
   Surgery                                  3 (5.8%)        7 (13.2%)                               0.1230
   Chemotherapy                             39 (76.4%)      36 (67.9%)                              0.1092
   Radiotherapy                             9 (17.6%)       12 (22.6%)                              0.1589
                                                                                                    
  **Expression of estrogen receptor**                                                               
   Positive                                 3 (5.8%)        9 (16.9%)                               0.0491
   Negative                                 8 (15.6%)       14 (26.4%)                              
   Not available                            40 (78.4%)      30 (56.6%)                              
                                                                                                    
  **Expression of progesterone receptor**                                                           
   Positive                                 3 (5.8%)        9 (16.9%)                               0.0302
   Negative                                 7 (13.7%)       14 (26.4%)                              
   Not available                            41 (80.3%)      30 (56.6%)                              
                                                                                                    
  **HER 2 expression**                                                                              
   1+                                       1 (1.9%)        4 (7.5%)                                0.4047
   2+                                       1 (1.9%)        0 (0%)                                  
   3+                                       3 (5.8%)        4 (7.5%)                                
   Not available                            46 (90.1%)      45 (84.9%)                              

###### 

Median survival for vaccinated patients.

  FORMULATION                                              MEDIAN (MONTHS)
  -------------------------------------------------------- -----------------
  Non emulsive-SC (900 μg) n = 51                          23,633
  Emulsive-IM (200 μg) n = 53                              8,233
  Global n = 104                                           15,833
  Log rank *P* = 0.001/HR (95% CI): 0.450 (0.273--0.740)   

###### 

Median survival (months) for patients vaccinated with either the nonemulsive or the emulsive formulation according to the site of metastases.

  ---------------------------------------------------------------------------------------------------------------------
  SITE OF METASTASES                                                       FORMULATION       GLOBAL            
  ------------------------------------------------------------------------ ----------------- ----------------- --------
  Non visceral n = 45                                                      31,633 (n = 24)   16,533 (n = 21)   22,533

  Visceral n = 48                                                          21,033 (n = 24)   6,267 (n = 24)    8,800

  Non visceral (log rank *P* = 0.118)/HR (95% CI): 0.535 (0.241--1.186)\                                       
  Visceral (log rank *P* = 0.005)/HR (95% CI): 0.375 (0.184--0.766)                                            
  ---------------------------------------------------------------------------------------------------------------------

###### 

Median survival (months) for patients vaccinated with either the nonemulsive or the emulsive formulation according to the disease stage.

  ---------------------------------------------------------------------------------------------------------------------
  STAGE                                                                      FORMULATION       GLOBAL            
  -------------------------------------------------------------------------- ----------------- ----------------- ------
  Stage I or II n = 50                                                       26.667 (n = 30)   11.833 (n = 20)   19.3

  Stage III or IV n = 35                                                     9.533 (n = 16)    6,267 (n = 19)    8,8

  Stage I or II (log rank *P* = 0.002)/HR (95% CI): 0.311 (0.140--0.688)\                                        
  Stage III or IV (log rank *P* = 0.263)/HR (95% CI): 0.618 (0.264--1.447)                                       
  ---------------------------------------------------------------------------------------------------------------------

###### 

Most frequent AEs according to the formulation.

  SYSTEM ORGAN CLASS                                     ADVERSE EVENT   FORMULATION                             
  ------------------------------------------------------ --------------- ------------- ------ ----- ------ ----- ------
  General disorders and administration site conditions   Site reaction   176           42.3   27    25     203   38.7
  Asthenia                                               27              6.5           5      4.6   32     6.1   
  Fever                                                  26              6.2           1      0.9   27     5.2   
  Chills                                                 15              3.6           5      4.6   20     3.8   
                                                                                                                 
  Nervous system disorders                               Headache        25            6      4     3.7    29    5.5
  Metabolism and nutrition disorders                     Anorexia        4             0.9    3     2.7    7     1.3
  Gastrointestinal disorders                             Diarrhea        2             0.4    1     0.9    3     0.5
  Musculoskeletal and connective tissue disorders        Muscle pain     3             0.7    8     7.4    11    2.1
  Arthralgia                                             5               1.2           1      0.9   6      1.1   
  Other                                                  Other           133           31.9   53    49.1   186   35.4

###### 

Intensity of AEs.

  GRADE   FORMULATION                            
  ------- ------------- ------ ---- ------ ----- ------
  1       381           91.6   84   77.8   465   88.7
  2       24            5.8    7    6.5    31    5.9
  3       6             1.4    9    8.3    15    2.9
  4       0             0      1    0.9    1     0.2
  5       5             1.2    7    6.5    12    2.3
